Brookline Capital Management Estimates Kura Oncology FY2029 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of Kura Oncology in a note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will earn $12.19 per share for the year. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

A number of other research analysts have also issued reports on KURA. Bank of America reduced their price target on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Scotiabank lowered their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and reduced their price target for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Finally, TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.38.

Kura Oncology Stock Performance

Shares of NASDAQ KURA opened at $7.32 on Thursday. Kura Oncology has a 12-month low of $7.18 and a 12-month high of $24.17. The company has a market cap of $569.23 million, a PE ratio of -3.10 and a beta of 0.81. The stock has a 50 day simple moving average of $11.75 and a 200-day simple moving average of $16.95. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Institutional Trading of Kura Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in KURA. nVerses Capital LLC bought a new position in shares of Kura Oncology in the third quarter valued at $25,000. The Manufacturers Life Insurance Company grew its holdings in shares of Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after acquiring an additional 1,976 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in shares of Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after purchasing an additional 2,076 shares during the period. Hsbc Holdings PLC lifted its holdings in shares of Kura Oncology by 13.4% during the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after purchasing an additional 2,167 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Kura Oncology by 0.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.